

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization

International Bureau

(43) International Publication Date  
11 November 2021 (11.11.2021)



(10) International Publication Number  
**WO 2021/225968 A1**

(51) International Patent Classification:

C07D 211/62 (2006.01) A61P 1/00 (2006.01)  
C07D 405/12 (2006.01) A61K 31/4468 (2006.01)

(21) International Application Number:

PCT/US2021/030493

(22) International Filing Date:

03 May 2021 (03.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/019,829 04 May 2020 (04.05.2020) US

(71) Applicant: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP).

(72) Inventors; and

(71) Applicants (for US only): **GIBSON, Tony S.** [US/US]; c/o Takeda California, Inc., 9625 Towne Centre Drive, San Diego, California 92121 (US). **SWANN, Steve** [US/US]; c/o Takeda California, Inc., 9625 Towne Centre Drive, San Diego, California 92121 (US).

(74) Agent: **RUSO, Matthew J** et al.; c/o Takeda California, Inc., 9625 Towne Centre Drive, San Diego, California 92121 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES



(57) Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein m, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, X<sup>1</sup>, X<sup>2</sup>, X<sup>3</sup> and X<sup>4</sup> are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with the 5-HT<sub>4</sub> receptor.



WO 2021/225968 A1